Patrick Machado, J.D.

Board Member

Mr. Machado co-founded Medivation in 2003 and served as chief business officer from 2009 to 2014, chief financial officer from 2004 until his retirement in 2014, and as a member of its board of directors from April 2014 until the company was acquired by Pfizer in September 2016. His earlier experience includes senior finance, legal and business development roles at ProDuct Health and Chiron. He currently serves as a director for several biotechnology companies, including Adverum, Chimerix and Scynexis, and previously served as a director of Endocyte prior to its acquisition by Novartis. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado received a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University.

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb